Damian Mikulski

Damian Mikulski, MD, PhD, is a physician-scientist and board-certified hematologist. From the beginning of his professional career, he has been affiliated with the Department of Biostatistics and Translational Medicine at the Medical University of Lodz and the Department of Hemato-Oncology and Internal Medicine with the Day Chemotherapy Unit at the M. Kopernik Memorial Regional Center for Oncology and Traumatology in Łódź, Poland.

His research focuses on the application of data science and biostatistical methods in oncohematology. In 2025, he earned his PhD with distinction for his dissertation entitled “The Role of Serum-Free miRNAs in Predicting Outcomes, Complications and Toxicity in Autologous Hematopoietic Stem Cell Transplantation.” In the same year, he completed a research internship at the MD Anderson Cancer Center, Houston, Texas, supported by the Prof. Franciszek Walczak Scholarship from the Polish National Agency for Academic Exchange (NAWA).

Dr. Mikulski is a recipient of the Preludium-21 grant from the National Science Centre (NCN) and the 7th DKMS Foundation Research Grant. His scientific interests include biomarkers, the biology and treatment of hematologic malignancies - particularly multiple myeloma - and the integration of clinical and computational approaches in translational research.

He has co-authored publications in leading journals, including Lancet Oncology, Lancet Haematology, and Biomarker Research, and is involved in multiple clinical trials and non-commercial research projects. Dr. Mikulski actively collaborates with national research consortia, including the Polish Myeloma Consortium, the Polish Adult Leukemia Group (PALG), and the Polish Lymphoma Research Group (PLRG).

He combines clinical experience with research expertise, enabling him to conduct studies of high practical and translational relevance.